[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591154":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":63,"collaborators":10,"id":65,"slug":10,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"TScan Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"No study drug will be administered during this trial. Participants previously treated with TSC-100 or TSC-101 in a TScan study will be evaluated for long-term safety and efficacy.",[13],"Other: Observational",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"OTHER","Long Term Follow-Up for participants treated with TSC-100 or TSC-101 TCR-T products",[9],[20],{"name":21,"affiliation":22,"role":23},"Michelle Matzko, MD","Medical Monitor","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Madhavi Desai","CONTACT","(857) 399-9832","medicalaffairs@tscan.com",[31,50],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-117.97729,34.13945,{"lat":43,"lon":42},[46,48],{"name":47,"role":27,"phone":10,"phoneExt":10,"email":10},"Monzr M Al Malki, MD",{"name":47,"role":49,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":51,"status":33,"city":52,"state":52,"zip":53,"country":37,"countryCode":38,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Mount Sinai","New York","10029-6696",{"type":40,"coordinates":55},[56,57],-74.00597,40.71427,{"lat":57,"lon":56},[60,62],{"name":61,"role":27,"phone":10,"phoneExt":10,"email":10},"Alla Keyzner, MD",{"name":61,"role":49,"phone":10,"phoneExt":10,"email":10},{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100591154",false,"NCT06976736","A Long Term Follow-up Study of TScan TCR-T Products","A Long-term Follow-up Study to Assess Safety in Participants Who Received an Investigational T-Cell Receptor Engineered T-Cell (TCR-T) Product","LTFU","Inclusion Criteria:\n\n* Participants who received a TCR-T cellular therapy in a clinical study sponsored by TScan Therapeutics.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* None","ALL","18 Years","110 Years",{"count":76,"type":77},1000,"ESTIMATED","OBSERVATIONAL","The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored for 15 years from the date of TCR-T cell therapy administration to assess long-term safety and efficacy.",[81,72,82],"AML","MDS",[84,85,86,87,88,89,90],"TSCAN","Cell Therapies","TCR-T Cell Therapy","Long Term Follow-Up (LTFU)","TSC-101","TSC-100","TSCAN-001","2025-09-02",{"date":93,"type":94},"2025-09-10","ACTUAL",{"date":96,"type":77},"2025-09-09",{"date":98,"type":77},"2040-09",{"name":5,"class":6},2]